Dec 5 (Reuters) - Medical device maker Insulet

convinced a jury that Korean rival EOFlow owes it

$452 million in damages for stealing trade secrets related to

insulin pumps, according to a verdict made public in

Massachusetts federal court on Thursday.

The jury in its verdict on Tuesday agreed with Insulet that

EOFlow stole the Acton, Massachusetts-based company's secrets in

order to create a competitor to Insulet's ( PODD ) Omnipod, a wearable

insulin pump for diabetes patients.

Spokespeople for EOFlow did not immediately respond to a

request for comment on the verdict. Insulet president Jim

Hollingshead said the company was "extremely pleased" with the

verdict.

EOFlow stock was down nearly 30% at the close of Thursday

trading on Korea's stock market.

Insulet sued EOFlow last year. Its lawsuit said EOFlow hired

away former Insulet employees to develop its EOPatch, an insulin

device similar to Insulet's ( PODD ) Omnipod.

After failing for six years to design its own patch pump,

the lawsuit said EOFlow began selling a "completely redesigned"

EOPatch that was "strikingly similar" to the Omnipod less than

two years after taking advantage of the former Insulet

employees' confidential knowledge.

EOFlow denied the allegations.

Medtronic ( MDT ) announced last May that it would acquire

EOFlow but canceled the deal last December, citing "multiple

breaches" of their agreements.